Brain+

0,26 DKK +2,77 %

Ole ensimmäinen seuraaja

Brain+ are a pharmaceutical company. The company specializes in research and development for the treatment of dementia and Alzheimer's. The product portfolio includes, for example, cognitive stimulation therapy. In addition to the main business, service and associated ancillary services are also offered. The business is run with the largest presence in Europe.

Liikevaihto

EBIT %

P/E -luku

Osinkotuotto %

Tavoitehinta

Suositus

Päivitetty

First North Denmark

BRAINP

Päivän matalin / päivän korkein hinta

0,24 / 0,271 DKK

Markkina-arvo

11,51 milj. DKK

Vaihto

55,59 t. DKK

Vaihtomäärä, kappaletta

216 t.

Pörssikalenteri

Ylimääräinen yhtiökokous

11.10.2023

Suurimmat omistajat
Lähde: Millistream Market Data AB

Omistaja	Osuus	Ääniä
Kim Baden-Kristensen	15,4 %	15,4 %
Ulrik Ditlev Eriksen	9,3 %	9,3 %

Inderes Premium

Premium ei aktivoitu

Tämä sisältö on vain Inderes Premium -käyttäjille.

Kirjaudu sisään Lue lisää

Näytä Kaikki sisältötyypit

Brain+ A/S announces the exercise price for its warrants of series TO 2

Pörssitiedote29.09.2023

Brain+

Pörssikalenteri

Suurimmat omistajatLähde: Millistream Market Data AB

Inderes Premium

Brain+ A/S announces the exercise price for its warrants of series TO 2

Brain+ A/S: Brain+ has convened an EGM to add a strong digital health industry profile to its board of directors

Brain+ A/S: Notice of Extraordinary General Meeting

Brain+ A/S: Brain+ online investor meeting: Status update, warrant exercise and Q&A

Brain+ A/S: Brain+ awarded an EUopSTART grant by the Danish Innovation Fund to support 2[nd] stage of its EIC Accelerator application

Brain+ A/S: Brain+ to present at DTx East 2023, a global summit for the digital therapeutics' community, held in Boston, US on 26-28 September

Brain+ A/S: Two Brain+ grant applications pass first evaluation gate with unanimous support from evaluators

Brain+ A/S: Brain+ secures intellectual property rights for CST-Therapist Companion in the EU and the United Kingdom

Brain+ A/S: Summary of H1 2023 report: Brain+ has closed new sales contracts, built key customer engagement, developed a new product concept, achieved technology validations and secured new funding

Brain+ A/S: Brain+ has submitted new public grant applications to raise up to DKK 67 million to develop and scale its digital dementia products

Brain+ A/S: Brain+ Online Investor Update

Brain+ A/S: Brain+ and Danish municipalities are advancing the development of version 2.0 of the CST-Therapist Companion

Brain+ A/S: Breakthrough Alzheimer's drug approval seen to renew dementia drug investments and increase the potential for digital dementia therapies - good news for Brain+

Brain+ A/S: Brain+ presents at the 5[th] Annual DTx (Digital Therapeutics) Europe conference

Brain+ A/S carries out a directed issue as compensation to guarantors of its unit rights issue

Brain+ A/S announces the first day of trading for the new shares and warrants from its rights issue

Brain+ A/S announces a delay of the first day of trading for the new shares from its rights issue

Brain+ A/S published the outcome of its rights issue of units

Minutes of the Annual General Meeting 2023 in Brain+ A/S

Brain+ A/S: Brain+ showcased at Danish Dementia Days and at Altenpflege in Germany, Europe's largest elderly care conference

Suurimmat omistajat
Lähde: Millistream Market Data AB